Header Logo

Connection

Jonathan Kay to Gadolinium

This is a "connection" page, showing publications Jonathan Kay has written about Gadolinium.
Connection Strength

3.250
  1. Todd DJ, Kay J. Gadolinium-Induced Fibrosis. Annu Rev Med. 2016; 67:273-91.
    View in: PubMed
    Score: 0.483
  2. Schmidt-Lauber C, Bossaller L, Abujudeh HH, Vladimer GI, Christ A, Fitzgerald KA, Latz E, Gravallese EM, Marshak-Rothstein A, Kay J. Gadolinium-based compounds induce NLRP3-dependent IL-1? production and peritoneal inflammation. Ann Rheum Dis. 2015 Nov; 74(11):2062-9.
    View in: PubMed
    Score: 0.433
  3. Bernstein EJ, Schmidt-Lauber C, Kay J. Nephrogenic systemic fibrosis: a systemic fibrosing disease resulting from gadolinium exposure. Best Pract Res Clin Rheumatol. 2012 Aug; 26(4):489-503.
    View in: PubMed
    Score: 0.381
  4. Kay J, Czirj?k L. Gadolinium and systemic fibrosis: guilt by association. Ann Rheum Dis. 2010 Nov; 69(11):1895-7.
    View in: PubMed
    Score: 0.337
  5. Kay J. Nephrogenic systemic fibrosis: a gadolinium-associated fibrosing disorder in patients with renal dysfunction. Ann Rheum Dis. 2008 Dec; 67 Suppl 3:iii66-9.
    View in: PubMed
    Score: 0.295
  6. Todd DJ, Kay J. Nephrogenic systemic fibrosis: an epidemic of gadolinium toxicity. Curr Rheumatol Rep. 2008 Jul; 10(3):195-204.
    View in: PubMed
    Score: 0.287
  7. Kay J. Gadolinium and nephrogenic systemic fibrosis: the evidence of things not seen. Cleve Clin J Med. 2008 Feb; 75(2):112, 114, 117.
    View in: PubMed
    Score: 0.279
  8. Todd DJ, Kagan A, Chibnik LB, Kay J. Cutaneous changes of nephrogenic systemic fibrosis: predictor of early mortality and association with gadolinium exposure. Arthritis Rheum. 2007 Oct; 56(10):3433-41.
    View in: PubMed
    Score: 0.272
  9. Bernstein EJ, Isakova T, Sullivan ME, Chibnik LB, Wolf M, Kay J. Nephrogenic systemic fibrosis is associated with hypophosphataemia: a case-control study. Rheumatology (Oxford). 2014 Sep; 53(9):1613-7.
    View in: PubMed
    Score: 0.107
  10. Daftari Besheli L, Aran S, Shaqdan K, Kay J, Abujudeh H. Current status of nephrogenic systemic fibrosis. Clin Radiol. 2014 Jul; 69(7):661-8.
    View in: PubMed
    Score: 0.106
  11. Wang Y, Alkasab TK, Narin O, Nazarian RM, Kaewlai R, Kay J, Abujudeh HH. Incidence of nephrogenic systemic fibrosis after adoption of restrictive gadolinium-based contrast agent guidelines. Radiology. 2011 Jul; 260(1):105-11.
    View in: PubMed
    Score: 0.088
  12. Nazarian RM, Mandal RV, Kagan A, Kay J, Duncan LM. Quantitative assessment of dermal cellularity in nephrogenic systemic fibrosis: a diagnostic aid. J Am Acad Dermatol. 2011 Apr; 64(4):741-7.
    View in: PubMed
    Score: 0.087
  13. Kay J, Bazari H, Avery LL, Koreishi AF. Case records of the Massachusetts General Hospital. Case 6-2008. A 46-year-old woman with renal failure and stiffness of the joints and skin. N Engl J Med. 2008 Feb 21; 358(8):827-38.
    View in: PubMed
    Score: 0.070
  14. Le LP, Garibyan L, Lara D, Finberg KE, Iafrate AJ, Duncan LM, Kay J, Nazarian RM. Fibrosis-associated single-nucleotide polymorphisms in TGFB1 and CAV1 are not associated with the development of nephrogenic systemic fibrosis. Am J Dermatopathol. 2013 May; 35(3):351-6.
    View in: PubMed
    Score: 0.025
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.